The GPVI – Fc Fusion Protein Revacept Reduces Thrombus Formation and Improves Vascular Dysfunction in Atherosclerosis without Any Impact on Bleeding Times
Open Access
- 12 August 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (8), e71193
- https://doi.org/10.1371/journal.pone.0071193
Abstract
Glycoprotein VI (GPVI) is a key platelet receptor which mediates plaque-induced platelet activation and consecutive atherothrombosis, but GPVI is also involved in platelet-mediated atheroprogression. Therefore, interference in GPVI-mediated platelet activation has the potential to combine short-term and long-term beneficial effects, specificity and safety especially regarding bleeding complications. We investigated the effects of the soluble dimeric GPVI receptor fusion protein, Revacept, an antagonist of collagen-mediated platelet activation, in an animal model of atherosclerosis: twenty week old rabbits, which had been fed on a cholesterol-rich diet for 8 weeks, received Revacept (8 mg/kg) or control twice weekly for 4 weeks. Pharmacokinetics indicated a slight accumulation of the drug in the serum after repeated dosing of Revacept for 3 weeks. A significant improvement of endothelial dysfunction after 0.06 and 0.6 µg/min acetylcholine and a significant decrease of vessel wall thickening were found after Revacept treatment. Accordingly, aortic vessel weight was reduced, and plaque sizes, macrophage and T-cell invasion tended to be reduced in histological evaluations. Bleeding time was determined after tail clipping in mice. Revacept alone or in combination with widely used anti-platelet drugs revealed a high safety margin with no prolongation of bleeding times. Repeated doses of Revacept led to a significant improvement of endothelial dysfunction and vascular morphology in atherosclerotic rabbits. Furthermore, no influence of Revacept on bleeding time alone or in combinations with various anti-platelet drugs was found in mice. Thus, the inhibition of collagen-mediated platelet interaction with the atherosclerotic endothelium by Revacept exerts beneficial effects on morphology and vascular function in vivo and seems to have a wide therapeutic window without influencing the bleeding time.Keywords
This publication has 18 references indexed in Scilit:
- Novel Antiplatelet Drug Revacept (Dimeric Glycoprotein VI-Fc) Specifically and Efficiently Inhibited Collagen-Induced Platelet Aggregation Without Affecting General Hemostasis in HumansCirculation, 2011
- Impact of glycoprotein VI and platelet adhesion on atherosclerosis—A possible role of fibronectinJournal of Molecular and Cellular Cardiology, 2010
- A 2-Step Mechanism of Arterial Thrombus Formation Induced by Human Atherosclerotic PlaquesJournal of the American College of Cardiology, 2010
- Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary InterventionNew England Journal of Medicine, 2008
- The immunoadhesin glycoprotein VI-Fc regulates arterial remodelling after mechanical injury in ApoE−/− miceCardiovascular Research, 2008
- Platelets in inflammation and atherogenesisJCI Insight, 2005
- Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivoThe FASEB Journal, 2003
- Activated platelets trigger an inflammatory response and enhance migration of aortic smooth muscle cellsThrombosis Research, 2003
- A Crucial Role of Glycoprotein VI for Platelet Recruitment to the Injured Arterial Wall In VivoThe Journal of Experimental Medicine, 2002
- A Critical Role of Platelet Adhesion in the Initiation of Atherosclerotic Lesion FormationThe Journal of Experimental Medicine, 2002